SALT LAKE CITY--(BUSINESS WIRE)--Great Basin Scientific, Inc. (NASDAQ:GBSN; GBSNU), a molecular diagnostics company, confirmed today that, the Company’s publicly traded unit (NASDAQ: GBSNU) has separated into its component parts of eight Series C Warrants and one share of Series E Convertible Preferred Stock. In connection with the separation of the Units, the Units were delisted from The Nasdaq Capital Market effective August 25, 2015.
The common stock of the Company (NASDAQ: GBSN) will remain listed on The Nasdaq Capital Market and is unaffected by the delisting of the Units. For instructions and forms regarding the conversion of the Series E Convertible Preferred Stock or the exercise of the Series C Warrants, please see the investor relations portion of the Company’s website at http://client.irwebkit.com/gbscience.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.